Epitranscriptomics in Cancer: How RNA Modifications Are Shaping Precision Oncology

 

Epitranscriptomics in Cancer: How RNA Modifications Are Shaping Precision Oncology

Introduction

Cancer biology is increasingly understood as a complex network of genetic, epigenetic, transcriptional, and post-transcriptional processes. While genomics has transformed the understanding of mutations and alterations that drive cancer, researchers are now focusing on another important layer of biological regulation: the chemical modification of RNA molecules.

This emerging field is known as epitranscriptomics.

RNA was traditionally viewed primarily as an intermediate molecule that carries genetic information from DNA to proteins. Modern RNA biology has demonstrated that RNA molecules are extensively modified after transcription and that these modifications can influence RNA stability, processing, localization, translation, degradation, and interactions with regulatory proteins. More than 170 RNA modifications have been identified across different RNA species, creating a complex regulatory landscape beyond the information encoded in the nucleotide sequence itself.

In cancer, this additional regulatory layer is attracting growing attention. Alterations in RNA modification pathways can influence tumor-cell proliferation, metabolism, differentiation, immune evasion, metastasis, cancer stemness, and response to therapy. Among the best-studied modifications are N6-methyladenosine (m6A), 5-methylcytosine (m5C), N1-methyladenosine (m1A), pseudouridine (Ψ), and other RNA modifications and editing events.

The significance of epitranscriptomics extends beyond understanding cancer biology. RNA modifications are increasingly being investigated as potential biomarkers, therapeutic targets, and components of precision oncology strategies.

This article explores how RNA modifications regulate cancer biology, why m6A has become a major focus of research, how epitranscriptomic alterations may contribute to treatment resistance, and what challenges remain before these discoveries can be translated into routine cancer care.

 

What Is Epitranscriptomics?

Epitranscriptomics refers to the study of chemical modifications that occur on RNA molecules and influence their biological behavior.

Similar to how epigenetic mechanisms can regulate gene activity without changing the underlying DNA sequence, RNA modifications can alter the fate and function of RNA without changing its nucleotide sequence.

These modifications can occur on several types of RNA, including:

• Messenger RNA (mRNA)
• Transfer RNA (tRNA)
• Ribosomal RNA (rRNA)
• Long non-coding RNA (lncRNA)
• Circular RNA (circRNA)
• MicroRNA and other non-coding RNAs

RNA modifications can affect how RNA molecules are processed, transported, translated, stabilized, or degraded. Different modifications may therefore influence protein production even when the underlying DNA sequence remains unchanged.

This creates an additional regulatory layer between the genome and the proteins produced by a cell.

In cancer, this layer can become dysregulated, potentially helping malignant cells adapt to changing environments, survive treatment, and acquire aggressive characteristics.

 

Why RNA Modifications Matter in Cancer

Cancer cells continuously adapt to genetic stress, metabolic changes, immune pressure, and anticancer treatments.

RNA modifications may contribute to this adaptability by controlling which RNA molecules remain stable, which are translated efficiently, and which are degraded.

For example, changes in RNA modification machinery may influence:

• Cancer-cell proliferation
• Apoptosis
• Cell differentiation
• Metabolic reprogramming
• Tumor invasion
• Metastasis
• Cancer stem-cell characteristics
• Immune evasion
• DNA damage responses
• Drug resistance
• Tumor-microenvironment interactions

Research has demonstrated that dysregulated RNA modification pathways can influence multiple cancer hallmarks. The effects are highly context dependent: the same RNA modification regulator may have different biological consequences in different tumor types or cellular states.

This context dependence is particularly important for precision oncology.

Rather than assuming that one RNA modification is universally cancer-promoting or cancer-suppressing, researchers increasingly examine the specific RNA, regulator, cell type, tumor subtype, and biological environment involved.

 

The Major RNA Modification Systems in Cancer

1. N6-Methyladenosine (m6A)

N6-methyladenosine, commonly abbreviated as m6A, is one of the most extensively studied internal RNA modifications in eukaryotic mRNA.

m6A can influence RNA stability, splicing, translation, export, and degradation. Its regulatory system is often described using three functional groups:

Writers

Writers are enzymes that add the modification to RNA.

Important components of the m6A machinery include:

• METTL3
• METTL14
• WTAP
• Associated regulatory proteins

Erasers

Erasers remove or reverse certain RNA modifications.

Two extensively studied m6A-associated demethylases include:

• FTO
• ALKBH5

Readers

Reader proteins recognize modified RNA and help determine what happens to the transcript.

Examples include proteins from the YTH domain family and other RNA-binding proteins.

Together, these components create a dynamic regulatory system that can change RNA fate according to cellular conditions.

 

2. 5-Methylcytosine (m5C)

m5C involves methylation of cytosine within RNA.

It has been identified in several RNA species, including:

• mRNA
• tRNA
• rRNA
• Non-coding RNA

RNA m5C can influence RNA structure, stability, translation, processing, and cellular localization.

Researchers have also investigated the involvement of m5C-associated enzymes in tumor growth, metabolic regulation, and therapy resistance. Recent reviews describe m5C as an increasingly important component of cancer epitranscriptomics, while emphasizing that its biological effects can differ according to the RNA and cellular context.

 

3. N1-Methyladenosine (m1A)

m1A is another RNA modification that can affect RNA structure and function.

It has been extensively studied in tRNA and rRNA and is also being investigated in mRNA and other RNA molecules.

Because m1A can influence RNA structure and interactions with cellular machinery, researchers are exploring its potential roles in:

• Translation
• Cellular stress responses
• Cancer-cell survival
• Tumor progression
• RNA regulation

Compared with m6A, the cancer biology of m1A remains less completely characterized, creating opportunities for further research.

 

4. Pseudouridine

Pseudouridine (Ψ) is an isomer of uridine and represents one of the most abundant RNA modifications.

Pseudouridylation can influence RNA structure and function and has been investigated across different RNA species.

Research has suggested that pseudouridine-related pathways may have potential relevance to cancer biology and biomarker development. However, substantial work remains necessary to determine how these modifications can be reliably measured and translated into clinical applications.

 

5. Other Emerging RNA Modifications

The epitranscriptomic landscape extends well beyond m6A, m5C, m1A, and pseudouridine.

Researchers are also investigating modifications and RNA-processing events involving:

• m7G
• m6Am
• N4-acetylcytidine (ac4C)
• 2′-O-methylation
• A-to-I RNA editing
• Other specialized RNA modifications

These mechanisms can affect RNA structure, translation, stability, processing, and interactions with proteins.

The growing number of identified RNA modifications demonstrates that RNA regulation is substantially more complex than a simple DNA-to-RNA-to-protein model.

 

How Do RNA Modifications Influence Cancer Cells?

One of the most important questions in epitranscriptomics is how a chemical modification on RNA ultimately changes cancer-cell behavior.

The answer involves multiple levels of regulation.

RNA Stability

Some RNA modifications can alter how long an RNA molecule survives inside the cell.

A transcript that remains stable for longer can potentially produce more protein.

If the affected transcript encodes a growth-promoting protein, changes in RNA stability could contribute to malignant behavior.

Translation

RNA modifications can influence how efficiently an RNA molecule is translated into protein.

This provides cancer cells with a mechanism for rapidly adjusting protein production without requiring new transcription.

RNA Splicing

RNA modifications can affect processing of precursor RNA and the production of different RNA isoforms.

Alternative splicing can be important in cancer because different isoforms may have different biological functions.

RNA Degradation

Modified RNA can be recognized by specific proteins that influence degradation or stabilization.

This creates another mechanism through which cells control gene expression.

RNA Localization

RNA molecules must reach appropriate cellular compartments to perform their functions.

RNA modifications can influence RNA localization and interactions with RNA-binding proteins.

Together, these mechanisms allow epitranscriptomic regulation to influence cancer-cell behavior at multiple levels.

 

Epitranscriptomics and Tumor Growth

Tumor growth requires cancer cells to continuously produce proteins that support proliferation and survival.

RNA modification systems can contribute to this process by altering the expression of transcripts involved in:

• Cell-cycle regulation
• Growth signaling
• Survival pathways
• Metabolism
• DNA repair
• Protein synthesis

The m6A pathway, in particular, has been linked to tumor initiation and progression in multiple cancer models.

However, the relationship is not universally linear. Depending on the cancer type and molecular context, specific RNA modification regulators may function in oncogenic or tumor-suppressive ways.

This complexity is one reason why epitranscriptomics may be particularly relevant to individualized cancer treatment.

 

RNA Modifications and Cancer Stemness

Cancer stem-like cells are associated with characteristics such as self-renewal, differentiation potential, and treatment resistance.

Epitranscriptomic mechanisms may help regulate these cellular states.

m6A-associated pathways, for example, have been linked to cancer stem-cell self-renewal and tumor-cell plasticity.

By modifying the stability or translation of specific transcripts, RNA modification machinery may influence whether tumor cells maintain stem-like characteristics or undergo differentiation.

Understanding this process could be important for developing strategies designed to target tumor populations that survive conventional treatment.

 

Epitranscriptomics and Cancer Metabolism

Cancer cells frequently reprogram their metabolism to support rapid growth and survival.

RNA modifications may participate in this metabolic adaptation by regulating transcripts involved in:

• Glucose metabolism
• Lipid metabolism
• Amino-acid metabolism
• Mitochondrial function
• Cellular stress responses

Recent research has highlighted connections between RNA modification pathways and metabolic reprogramming in cancer.

This creates an interesting intersection between epitranscriptomics and cancer metabolism.

Future precision-oncology approaches may potentially combine molecular information about RNA modifications with genomic and metabolic profiles to characterize individual tumors more comprehensively.

 

Epitranscriptomics and Tumor Microenvironment

Cancer cells do not exist independently.

They interact with immune cells, fibroblasts, endothelial cells, extracellular matrix components, and other cells within the tumor microenvironment.

RNA modifications may influence these interactions.

For example, epitranscriptomic regulation can affect pathways involved in:

• Immune signaling
• Cytokine production
• Immune-cell recruitment
• Tumor-associated inflammation
• Immune evasion
• Cellular stress

Research on m6A has particularly highlighted relationships between RNA modification machinery and the tumor microenvironment and antitumor immunity.

Understanding these relationships could eventually help researchers identify which patients may respond differently to immunotherapy.

 

RNA Modifications and Cancer Immunotherapy

Cancer immunotherapy depends on the ability of the immune system to recognize and attack malignant cells.

However, tumors can develop mechanisms that suppress immune responses.

Epitranscriptomic pathways may influence immune signaling and tumor-immune interactions, potentially affecting:

• Antigen presentation
• Interferon signaling
• Immune-cell activity
• Cytokine pathways
• Immune evasion
• Response to immune checkpoint therapy

Recent research has investigated RNA modification signatures as potential indicators of tumor immune status and therapeutic response. However, many such applications remain investigational and require clinical validation before routine use.

 

Epitranscriptomics and Cancer Therapy Resistance

One of the most important areas of epitranscriptomic cancer research is treatment resistance.

Cancer cells can survive therapy through multiple mechanisms, including:

• Genetic evolution
• Altered drug metabolism
• Changes in DNA repair
• Cancer-cell plasticity
• Stem-like states
• Microenvironmental adaptation
• Altered immune responses

RNA modifications may influence several of these processes.

Dysregulated m6A machinery, for example, has been associated in research studies with therapeutic resistance and altered responses to anticancer treatment.

This raises an important research question:

Could targeting RNA modification pathways make cancer cells more sensitive to existing therapies?

Preclinical studies are exploring this possibility, including combinations with chemotherapy, targeted therapies, and immunotherapy. However, most RNA-modification-targeted therapeutic strategies remain under investigation.

 

RNA Modifications as Cancer Biomarkers

A major attraction of epitranscriptomics is its potential for biomarker development.

A biomarker based on RNA modifications could potentially provide information about:

• Cancer subtype
• Disease progression
• Prognosis
• Treatment response
• Resistance
• Tumor biology
• Immune status

Researchers are studying RNA modification regulators as well as modification patterns themselves.

Importantly, biomarker research needs to move beyond statistical associations.

A clinically useful biomarker should demonstrate reproducible performance in appropriately designed patient populations and should provide information that can meaningfully support clinical decision-making.

Recent reviews have identified RNA modification patterns as promising candidates for diagnostic, prognostic, and predictive applications, while emphasizing the need for further validation and standardization.

 

Liquid Biopsy and Epitranscriptomics

Liquid biopsy has already become an important research area in precision oncology.

Blood-based samples can contain:

• Circulating tumor DNA
• Circulating tumor RNA
• Extracellular vesicles
• Exosomes
• Other tumor-derived molecular signals

RNA modifications detected in circulating RNA or extracellular vesicles could potentially provide additional information about tumor biology.

This creates an intersection between epitranscriptomics and liquid biopsy.

One potential advantage is that RNA-based biomarkers may capture dynamic biological changes that occur during disease progression or treatment.

However, technical challenges remain, including:

• Low abundance of some RNA species
• Sample quality
• Standardization
• Modification detection accuracy
• Biological heterogeneity
• Differences between tissues and circulating material

Further research is required before epitranscriptomic liquid-biopsy biomarkers become routine clinical tools.

 

Technologies Driving Epitranscriptomic Research

The growth of epitranscriptomics has been strongly connected to advances in molecular technologies.

Researchers are developing methods to:

• Identify modified RNA sites
• Quantify modification abundance
• Map RNA modifications across transcriptomes
• Determine modification stoichiometry
• Study RNA-protein interactions
• Analyze modification patterns at single-cell resolution
• Integrate RNA modification data with genomic and transcriptomic datasets

Techniques such as RNA immunoprecipitation sequencing and other modification-mapping approaches have helped expand knowledge of RNA modification landscapes.

Emerging single-cell and spatial technologies may further reveal how RNA modifications vary among different tumor-cell populations and within distinct regions of the tumor microenvironment.

 

Single-Cell Epitranscriptomics

Tumors are heterogeneous.

A tumor can contain multiple cancer-cell populations with different genetic, transcriptional, metabolic, and functional states.

Bulk RNA analysis averages signals across millions of cells and may therefore hide important differences between individual tumor-cell populations.

Single-cell approaches could help researchers investigate:

• Which cells carry specific RNA modifications
• How modification patterns change during tumor progression
• Which cells become therapy resistant
• How tumor cells interact with immune cells
• How epitranscriptomic states evolve during treatment

Although single-cell epitranscriptomics is technically challenging, it represents an important direction for future precision oncology research.

 

Spatial Epitranscriptomics

Cancer biology is strongly influenced by location.

A tumor cell near a blood vessel may experience a different environment from a tumor cell located in a hypoxic or immune-rich region.

Spatial approaches may eventually help researchers understand how RNA modification patterns vary according to tumor location.

Combining:

RNA modifications + single-cell analysis + spatial biology + genomics

could provide a more comprehensive picture of tumor organization.

This integrated approach may be particularly valuable for understanding treatment resistance and tumor evolution.

 

Artificial Intelligence and Epitranscriptomics

The amount of data generated by modern molecular profiling is increasing rapidly.

Artificial intelligence and machine learning may help researchers identify patterns across:

• RNA modification profiles
• Genomic alterations
• Transcriptomic data
• Proteomic data
• Clinical characteristics
• Treatment response
• Survival outcomes

Machine-learning models could potentially identify molecular signatures associated with disease characteristics or treatment response.

However, computational prediction alone does not establish clinical utility.

AI-derived epitranscriptomic biomarkers require biological validation, independent cohorts, reproducibility testing, and appropriate clinical evaluation.

The combination of AI and epitranscriptomics therefore represents a promising research direction rather than a fully established clinical technology.

 

Can RNA Modifications Become Therapeutic Targets?

The possibility of directly targeting RNA modification machinery has generated significant interest.

Potential strategies include targeting:

• RNA-modifying enzymes
• RNA demodifying enzymes
• RNA-binding reader proteins
• Specific RNA modification pathways
• Interactions between RNA modifications and oncogenic signaling

Researchers are investigating small molecules that modulate components of the m6A pathway and other RNA modification systems.

Preclinical studies have reported potential anticancer effects for some approaches, including possible combinations with existing therapies. However, translating these findings into safe and effective human treatments remains a major challenge.

 

Challenges in Developing Epitranscriptomic Therapies

Despite its promise, several challenges must be addressed.

Biological Complexity

A single RNA modification can influence multiple transcripts and pathways.

Therefore, manipulating one enzyme may produce widespread biological effects.

Context Dependence

The same modification may have different effects in different cancer types or cellular contexts.

Selectivity

A therapeutic agent must ideally affect cancer-associated RNA pathways without causing unacceptable effects in normal tissues.

Biomarker Standardization

Different laboratories may use different platforms and analytical methods.

Standardized measurement protocols are needed for reproducible clinical research.

Tumor Heterogeneity

Different cells within the same tumor may have different epitranscriptomic profiles.

Clinical Validation

Many findings currently come from cell lines, animal models, retrospective datasets, or early-stage studies.

Large prospective clinical studies will be needed to establish clinical utility.

 

Epitranscriptomics and Precision Oncology

Precision oncology aims to select treatment strategies according to the molecular characteristics of an individual patient's cancer.

Historically, precision oncology has focused heavily on:

• DNA mutations
• Copy-number alterations
• Gene fusions
• Gene expression
• Protein biomarkers

Epitranscriptomics could add another layer of information.

A future precision-oncology profile might potentially integrate:

Genomics + Transcriptomics + Epitranscriptomics + Proteomics + Metabolomics + Clinical Data

Such integration could help researchers develop more comprehensive models of tumor biology.

The goal would not simply be to identify whether a particular RNA modification exists, but to understand how the modification interacts with the patient's broader molecular landscape.

 

Future Directions of Epitranscriptomics in Cancer

The field is moving toward increasingly integrated and high-resolution approaches.

Future research may focus on:

1. More Accurate RNA Modification Mapping

Improved technologies could make it possible to identify modification sites more precisely.

2. Single-Cell Analysis

Researchers may increasingly characterize epitranscriptomic differences among individual tumor-cell populations.

3. Spatial Profiling

Spatial technologies may reveal how RNA modifications vary across different tumor regions.

4. Dynamic Monitoring

Repeated sampling could potentially help researchers monitor changes during treatment.

5. Combination Therapies

RNA modification-targeted approaches may be investigated alongside:

• Chemotherapy
• Targeted therapy
• Radiotherapy
• Immunotherapy

6. Biomarker Development

Epitranscriptomic signatures may be evaluated for diagnosis, prognosis, and treatment-response prediction.

7. AI-Enabled Molecular Modeling

Artificial intelligence could help integrate complex RNA modification datasets with clinical and molecular information.

8. Personalized RNA Therapeutics

Better understanding of RNA modification could also influence the development and optimization of RNA-based therapeutic technologies.

 

Why Epitranscriptomics Matters for Cancer Researchers

The importance of epitranscriptomics lies in its ability to explain biological behavior that may not be fully understood through DNA sequence analysis alone.

Two tumors may contain similar genetic alterations but behave differently because of differences in transcriptional, post-transcriptional, metabolic, or microenvironmental regulation.

RNA modifications may provide part of the explanation.

For researchers, this creates opportunities to investigate:

• New cancer mechanisms
• New biomarkers
• New therapeutic targets
• Treatment resistance
• Tumor evolution
• Immune regulation
• Cancer-cell plasticity
• Personalized treatment strategies

As technologies improve, epitranscriptomic information may become increasingly integrated into cancer research and, potentially, clinical precision-oncology frameworks.

 

The Road Ahead

The next phase of epitranscriptomics will require collaboration across multiple disciplines.

Molecular biologists, oncologists, bioinformaticians, pathologists, computational scientists, pharmacologists, and clinical researchers will all have important roles.

The field will also benefit from:

• Standardized experimental methods
• Large clinical datasets
• Multi-omics integration
• Longitudinal patient studies
• Better modification-detection technologies
• Functional validation
• Well-designed clinical trials

These efforts could help distinguish promising biological discoveries from biomarkers and therapeutic strategies that are truly ready for clinical application.

 

Conclusion

Epitranscriptomics is emerging as an important new layer of cancer biology and precision oncology.

RNA modifications such as m6A, m5C, m1A, and pseudouridine can influence RNA stability, translation, processing, localization, and cellular signaling. Their dysregulation has been associated with important cancer processes including tumor growth, metabolism, immune regulation, stemness, metastasis, and therapy resistance.

The growing ability to map and analyze RNA modifications is opening new possibilities for cancer biomarker discovery and therapeutic development. At the same time, the field remains scientifically complex, and many proposed biomarkers and therapeutic strategies still require rigorous validation.

The future of precision oncology may increasingly depend on integrating information from multiple molecular layers rather than relying on genomic alterations alone.

By combining genomics, transcriptomics, epitranscriptomics, proteomics, metabolomics, artificial intelligence, and clinical data, researchers may gain a more complete understanding of how individual tumors behave and respond to treatment.

As epitranscriptomic technologies continue to mature, RNA modifications could become an increasingly important component of the next generation of cancer research and personalized oncology.

 

Frequently Asked Questions (FAQs)

1. What is epitranscriptomics in cancer?

Epitranscriptomics is the study of chemical modifications that occur on RNA molecules and regulate their biological functions. In cancer, these modifications can influence gene expression, RNA stability, translation, tumor growth, immune responses, and treatment resistance.

2. What is m6A RNA modification?

m6A, or N6-methyladenosine, is one of the most extensively studied internal RNA modifications in eukaryotic mRNA. It can influence RNA stability, translation, splicing, and degradation and has been associated with multiple aspects of cancer biology.

3. What are RNA modification writers, erasers and readers?

Writers are enzymes that add specific RNA modifications, erasers remove or reverse certain modifications, and readers recognize modified RNA and influence its downstream fate.

4. Which RNA modifications are important in cancer research?

Major areas of research include m6A, m5C, m1A, pseudouridine, m7G, m6Am, ac4C, 2′-O-methylation, and RNA editing mechanisms such as A-to-I editing.

5. Can RNA modifications be used as cancer biomarkers?

RNA modifications and their regulatory proteins are being investigated as potential diagnostic, prognostic, and predictive biomarkers. However, many proposed biomarkers still require further validation before routine clinical use.

6. Can RNA modifications predict cancer treatment response?

Research suggests that certain RNA modification patterns may be associated with treatment response or resistance. However, predictive performance needs to be validated in appropriately designed clinical studies.

7. Can RNA modifications be targeted with cancer drugs?

Researchers are investigating drugs that target RNA-modifying enzymes and associated proteins. Several approaches have shown potential in preclinical studies, but many remain experimental.

8. How are RNA modifications detected?

Researchers use a range of molecular and sequencing-based techniques to identify and map RNA modifications. The available methods differ in their resolution, sensitivity, specificity, and ability to quantify modification levels.

9. What is the relationship between epitranscriptomics and precision oncology?

Epitranscriptomics may provide additional molecular information that complements genomic, transcriptomic, proteomic, and clinical data. This could contribute to more detailed molecular classification and personalized cancer-treatment strategies.

10. What is the future of epitranscriptomics in cancer research?

Future research is expected to focus on single-cell and spatial profiling, improved RNA-modification detection, biomarker validation, AI-assisted analysis, therapeutic targeting, and integration with multi-omics precision-oncology approaches.

 

About Oncology Summit-2027

The International Experts Summit on Oncology & Cancer Care (Oncology Summit-2027) will bring together researchers, oncologists, healthcare professionals, scientists, academicians, and industry experts to discuss emerging developments across oncology and cancer care.

International Experts Summit on Oncology & Cancer Care (Oncology Summit-2027)
March 25–27, 2027
Osaka, Japan

The summit provides an international platform for sharing research findings, discussing emerging technologies, exploring innovative cancer-treatment strategies, and connecting with experts working across different areas of oncology and cancer research.

Researchers and healthcare professionals interested in epitranscriptomics, RNA biology, precision oncology, cancer biomarkers, molecular oncology, cancer therapeutics, and related fields are invited to participate and share their latest research.